5414002026-01-012026-03-315414002026-03-315414002025-03-315414002025-04-012026-03-315414002026-01-012026-03-31in-capmkt:OtherExpenses1Member5414002025-04-012026-03-31in-capmkt:OtherExpenses1Member5414002026-03-31OtherNoncurrentFinancialAssetsDomain15414002026-03-31OtherNoncurrentFinancialAssetsDomain25414002026-03-31OtherNoncurrentAssetsDomain15414002026-03-31OtherCurrentFinancialAssetsDomain15414002026-03-31OtherCurrentAssetsDomain15414002026-03-31OtherNoncurrentFinancialLiabilitiesDomain15414002026-03-31OtherCurrentFinancialLiabilitiesDomain15414002026-03-31OtherCurrentFinancialLiabilitiesDomain25414002026-03-31OtherCurrentLiabilitiesDomain15414002026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15414002025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15414002026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15414002025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15414002026-01-012026-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares541400ZIMLABNOTLISTEDINE518E01015ZIM Laboratories LimitedMain BoardEquity2025-04-012026-03-312026-05-192026-05-12INRLakhsQuarterlyFourth quarterSingle segmentPharmacuetical Industry2026-05-1912:45:002026-05-1916:30:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31UnauditedConsolidated105273400061621000111435500049703700023596000-49383000173915000331030005102900033564100010649380004941700004941700018178000-616000012018000037399000000037399000496300042362000373980001000423610001000535003000100.760.76000.760.760.00420.01330.0249Notes : <BR> <BR> 1) The above statement of consolidated financial results of ZIM Laboratories Limited ('the Parent' or 'the Company') and its subsidiaries (together referred to as 'Group') were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 18 May 2026 and 19 May 2026. There are no qualifications in the audit report issued for the year ended 31 March 2026. <BR> <BR> 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI). <BR> <BR> 3) The consolidated financial results of the Group for the quarter & year ended 31 March 2025 were reviewed/audited by another auditor, who expressed an unmodified conclusion/opinion on those results on 20 May 2025 respectively. <BR> <BR> 4) The figures for the quarters ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures for the years ended as on that date and the year to date figures upto the end of third quarter of the respective financial years, on which auditors had performed a limited review. <BR> <BR> 5) The Group is principally engaged in a single business segment which is "pharmaceuticals". There is no separate reportable segment as per Ind AS 108 - Operating Segments. <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> Place: Nagpur Anwar S. Daud <BR> Date: 19 May 2026 Managing Director2025-04-012026-03-31AuditedConsolidated37440010001138300003857831000164047600074683000-61414000639038000132023000199780000115111700037757030008212800008212800034239000-104920002374700005838100000005838100021067000794480005838100007944800005350030001001.191.19001.191.190.00420.01130.0162Other Expenses335641000Other Expenses11511170001564323000587602000016940005183200036765500000500000003523100035731000459700022352000263578600093774800001090380000251219000182908000048730001529380000029095700027580850000053938710005350030002426533000296153600050002961541000415883000000832000042420300001042030000528406000813956000847200006445680007292880001342960001677540000192027000859400025763000019039240000024323300005393871000Other Financial Asset25187000Income tax asset10044000Other non-current assets22352000Other current financial assets4873000Other current assets290957000Other Financial Liabilities8320000Other current financial liabilities106866000Lease Liabilities27430000Other current liabilities192027000132023000-7304800011084000002128000-3490005842000003423000000130351000199780000000-32390000-2840900075000326400011349000000-18106000-232000004505550005326830000003734200004953410000000000056165000443865000000000000000000007500016800000-177532000-5634770000035000000000077600002483650001465350003938800001289500000-24120002818560002137200001803300023175300019466000251219000Measurements of defined employee benefit plans43120004312000Measurements of defined employee benefit plans-1385000-13850001256000-403000Exchange differences on translation of foreign operations19070001907000Exchange differences on translation of foreign operations220490002204900000496300021067000AuditedtrueDeloitte Haskins & Sells LLPtrue2027-07-31